🟢 Tscan Therapeutics is trading 9% up in after-hours trading with no clear company-specific catalyst

Tscan Therapeutics is trading at $0.23, up 9.09%, with no clear company-specific announcement identified to explain its after-hours rise.

• A recent filing proposes a November 20 vote on a reverse split ratio between 1-for-2 and 1-for-50, in response to Nasdaq’s minimum-bid-price deficiency; it does not establish a reason for this move.
• The Nasdaq was up 3.87%, which may support a broader risk-on explanation but does not confirm the cause of the stock’s after-hours move.